Aileron Therapeutics, Inc. (ALRN) financial statements (2020 and earlier)

Company profile

Business Address 490 ARSENAL WAY
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18253213212836
Cash and cash equivalents57101111812
Short-term investments1318212102024
Restricted cash and investments0000000
Other undisclosed current assets1211121
Total current assets:20263314223037
Noncurrent Assets
Operating lease, right-of-use asset66  
Property, plant and equipment0000774
Restricted cash and investments1111111
Other noncurrent assets 001111
Other undisclosed noncurrent assets  67   
Total noncurrent assets:7788985
TOTAL ASSETS:26344022303843
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3432453
Accounts payable1221232
Accrued liabilities1111010
Employee-related liabilities1111111
Debt00     
Other undisclosed current liabilities2222233
Total current liabilities:6655576
Noncurrent Liabilities
Long-term debt and lease obligation55  553
Long-term debt, excluding current maturities    553
Operating lease, liability55  
Other undisclosed noncurrent liabilities  55   
Total noncurrent liabilities:5555553
Total liabilities:10111010111210
Stockholders' equity
Stockholders' equity attributable to parent16233013202633
Common stock0000000
Additional paid in capital214214213189188187187
Accumulated other comprehensive income (loss)000 (0)(0)(0)
Accumulated deficit(198)(191)(183)(176)(168)(161)(154)
Total stockholders' equity:16233013202633
TOTAL LIABILITIES AND EQUITY:26344022303843

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(7)(8)(7)(7)(7)(7)(10)
Operating loss:(7)(8)(7)(7)(7)(7)(10)
Loss before gain (loss) on sale of properties:(7)(8)(7)(7)(7)(7)(10)
Other undisclosed net income (loss)0  0(0)  
Net loss:(7)(8)(7)(7)(7)(7)(10)
Other undisclosed net income attributable to parent 00  00
Net loss available to common stockholders, diluted:(7)(8)(7)(7)(7)(7)(9)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(7)(8)(7)(7)(7)(7)(10)
Comprehensive loss:(7)(8)(7)(7)(7)(7)(10)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)000(0)00
Comprehensive loss, net of tax, attributable to parent:(7)(8)(7)(7)(7)(7)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: